CytoDyn Inc. (CYDY) Form 10-Q — Oct 14, 2026
CytoDyn reported a Q1 FY2027 net loss of $19.9 million, roughly 3.6x the $5.5 million loss a year earlier, driven by a $12.3 million non-cash loss on note extinguishment and $3.9 million of private placement issuance costs, partially offset by a $3.2 million legal settlement revaluation gain.
Key figures
- Eps
- -0.01
- Total Debt
- 27200000
- Total Assets
- 19054000
- Cash Position
- 16359000
- Shares Outstanding
- 1454354000
- Ga Expense
- 2056000
- Rnd Expense
- 4521000
- Deal Price Per Unit
- 0.20889
- Operating Expenses
- 6577000
- Accumulated Deficit
- 950421000
- Warrants Outstanding
- 383876000
- Loss On Note Extinguishment
- 12272000
- Securities Class Action Accrual
- 11600000
- Gross Proceeds Private Placement
- 16200000
- Issuance Costs Private Placement
- 3921000
- Legal Settlement Revaluation Gain
- 3249000
- Shares Issued Private Placement Units
- 77400000
- Convertible Notes Plus Accrued Interest
- 35809000
- Standby Equity Purchase Agreement Limit
- 30000000
AI analysis
Red flags7 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.